All in all I like this news
In theory Starpharma raised a proxy of $38 million to fund development of novel drugs
Nothing wrong with that
Just another avenue to help commercialise products
Cheryl Maley, CEO of Starpharma, commented
This is just one of many ongoing efforts to prioritise the commercialisation of Starpharma’s DEP® platform and our partnerships to advance the application of the DEP® technology in high value novel therapeutic areas
My interpretation of M/S partnership announcement today is for development of new drugs that are in preclinical studies
Radiotheranostics
ADC's
etc
Shyam Masrani, Principal at Medicxi and Board representative of Petalion, commented: “While the field of targeted conjugates has experienced remarkable growth and led to the approval of several treatment options for patients with cancer, it is also evident that the current approaches have limitations. Medicxi is excited to support Petalion under the leadership of Dr Shahidi from the outset and we look forward to working closely with the Starpharma team to develop a highly differentiated and effective new medicine.”
As far as the Phase 2 in house Dep products........this has nothing to do with this agreement
Questions for the Webinar
Equity of 22.5% in Petalian
Is there an option to increase holding in entity. I figure a further 22.5% will bring stake to a maximum of 45% with the controlling interest being held by Medixi
Will the focus be on preclinical drugs currently being studied in Starpharma's labs
- Forums
- ASX - By Stock
- SPL
- Ann: Starpharma and Medicxi Partnership Petalion Therapeutics
Ann: Starpharma and Medicxi Partnership Petalion Therapeutics, page-38
-
-
- There are more pages in this discussion • 124 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SPL (ASX) to my watchlist
(20min delay)
|
|||||
Last
9.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $38.81M |
Open | High | Low | Value | Volume |
9.2¢ | 9.3¢ | 9.1¢ | $101.1K | 1.097M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 500000 | 9.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.3¢ | 89000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 500000 | 0.092 |
1 | 21168 | 0.091 |
7 | 98853 | 0.090 |
3 | 136462 | 0.089 |
2 | 45464 | 0.088 |
Price($) | Vol. | No. |
---|---|---|
0.093 | 89000 | 1 |
0.094 | 152000 | 2 |
0.095 | 33409 | 3 |
0.096 | 104177 | 1 |
0.098 | 119206 | 2 |
Last trade - 10.59am 21/10/2024 (20 minute delay) ? |
Featured News
SPL (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, Chief Executive Officer
Paul Long
Chief Executive Officer
SPONSORED BY The Market Online